Developer docs
API playgroundTry for free, no card

Search company profiles

True Diagnostics

Full company profile

uuid0008q17

Namestring
True Diagnostics
Legal namestring
True Diagnostics, Inc.
Websiteurl
truediag.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

True Diagnostics, Inc. is a privately held research, development, and manufacturing company founded in 2010 and headquartered in Carlsbad, California, specializing in rapid in-vitro immunodiagnostic test systems. The company builds its products around the proprietary TrueDX platform, anchored by a patented multi-point integrated calibration method that converts conventional qualitative lateral flow assays into quantitative tests with 18-month room-temperature shelf stability. The product portfolio includes the TrueDX Cassette, the TrueDXP Disposable Reader (a hand-held digital reader with OLED display and optional Bluetooth), the higher-spec TrueDX Reader (CMOS sensor, resistive touch screen, QC check, optional Wi-Fi), and supporting modules TrueDXQDF (quantum dot fluorescence for ~100x photo-bleaching stability vs. organic dyes) and TrueDXM (multiplexed picoliter-volume liquid handling). Assay menu spans thyroid, cardiac, cancer, fertility, and biologics monitoring panels.

Short descriptiontext

True Diagnostics is a Carlsbad, California-based developer and manufacturer of rapid in-vitro immunodiagnostic test systems built on its patented TrueDX multi-point calibration platform, serving point-of-care providers, OTC self-testers, OEM partners, and government biodefense programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid immunoassays, point-of-care diagnostics, in-vitro immunodiagnostics, lateral flow assays, diagnostic test readers
Industry4 codes
PRIMARYHLAHAAAJ
Companion Diagnostics (CDx) & Precision Medicine IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In-Vitro Immunodiagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Test Systems and Reagents
TypeHardware Sales
Description

Research, development and manufacturing company specializing in rapid in-vitro immunodiagnostic test systems and reagents. Revenue generated from sale of proprietary diagnostic cassettes, disposable readers, and assay reagents.

truediag.com
2Over-the-Counter Products
TypeOne Time License
Description

Disposable readers and test products sold through retail pharmacy chains for consumer self-testing.

truediag.com
3Partnership Development Services
TypeProfessional Services
Description

Provides design, development, and manufacturing services for assay development to commercial partners. Partners with companies to develop tests with tough specifications including high sensitivity, quantification, multiplexing, and extended shelf life stability.

truediag.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1TruDia
Description

Brand name used in logo and product references

truediag.com
+7 more records
Core offering1 text field

True Diagnostics is a research, development, and manufacturing company that develops and produces proprietary rapid in-vitro immunodiagnostic test systems and reagents. Its core offering centers on the TrueDX platform—patented lateral-flow cassettes with integrated calibration paired with hand-held digital readers—and a menu of quantitative assay panels (thyroid, cardiac, cancer markers, fertility, biologics) sold to clinical providers, OTC retail consumers, and commercial assay-development partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • All TrueDX Assays stable at room temperature for up to 18 months
+2 more records
Product overview1 text field

True Diagnostics is a research, development, and manufacturing company specializing in rapid in-vitro immunodiagnostic test systems. The core product portfolio is built around the proprietary TrueDX technology platform, which includes the TrueDX Cassette (lateral flow test with patented internal calibration), paired with the TrueDXP Disposable Reader (hand-held digital reader with OLED display and optional Bluetooth) and the TrueDX Reader (higher-specification platform with CMOS sensor and touch screen). Supporting modules include TrueDXQDF (quantum dot fluorescence enhancement for improved sensitivity) and TrueDXM (multiplexing capability). The company offers a range of TrueDX Assays spanning thyroid (TSH, Free-T4), cardiac (NT-proBNP, CKMB, Troponin I, Myoglobin), cancer (PSA, AFP, CEA), fertility (HCG), and biologics monitoring (Rituximab, Natalizumab, Trastuzumab) profiles. All assays are stable at room temperature for up to 18 months.

Product and service6 records
1TrueDX Cassette
CategoryDiagnostic Test Cassettes
2TrueDXP Disposable Reader
CategoryDiagnostic Readers
3TrueDX Reader
CategoryDiagnostic Readers
4TrueDX Assays
CategoryDiagnostic Test Assays / Reagents
5TrueDXQDF Quantum Dot Fluorescence System
CategoryDiagnostic Optical Modules
6TrueDXM Multiplexed Assay System
CategoryDiagnostic Assay Modules
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-20
Description

BARDA awarded True Diagnostics a project valued at approximately $11 million to develop a rapid diagnostic test capable of detecting Ebola and Marburg viruses. The project focuses on accelerating biothreat response and supporting future outbreak preparedness. This represents a significant government partnership for advanced diagnostic development.

2Abreos Biosciences
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Brad Messmer, CEO of Abreos Biosciences, is quoted endorsing the TrueDX technology platform, stating it bridges the gap between the ease and speed of traditional qualitative lateral flow assays and the quantitative rigor needed for clinical assays. Abreos appears to be an early adopter and strategic user of the technology.

truediag.com
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Company states that global partners entrust them with concepts, design, development, manufacturing and support processes to grow their iconic brands. These are unspecified commercial partnerships for assay development and manufacturing services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

QuidelOrtho is a major diagnostics company with a broad rapid immunoassay and point-of-care testing portfolio (e.g., Sofia, Triage), directly overlapping with TrueDX's POC and OTC diagnostic positioning and serving similar physician office, urgent care, and retail channels.

TypeDirect peer
Description

Chembio develops rapid point-of-care immunodiagnostic tests, including lateral flow assays for infectious disease and biothreat detection — closely comparable to TrueDX's cassette-plus-reader model and BARDA-aligned focus on emerging pathogen preparedness.

TypeDirect peer
Description

OraSure is best known for OTC consumer diagnostics (e.g., OraQuick HIV, HCV) sold through retail pharmacy, and also serves biodefense and public health markets — directly parallel to TrueDX's OTC self-test and biothreat segments.

4Abbott (Diagnostics)
TypeBroad incumbent
Description

Abbott operates the largest point-of-care diagnostics franchise globally, including the i-STAT system, Binax Now, and extensive OTC rapid tests — a dominant incumbent against whom TrueDX's POC and OTC reader must compete for hospital and retail shelf space.

TypeBroad incumbent
Description

BD's Diagnostic Systems segment includes the Veritor point-of-care immunoassay platform and a large biodefense/CDC product portfolio, making it both a competitor in POC diagnostics and a potential federal contracting counterpart to TrueDX on BARDA-style awards.

TypeDirect peer
Description

Response Biomedical develops rapid quantitative immunoassays (RAMP platform) used in point-of-care clinical and biodefense settings — a near-direct comparability to TrueDX's cassette-plus-reader quantitative approach, including cardiovascular and infectious disease markers.

7LumiraDx
TypeEmerging player
Description

LumiraDx built a connected point-of-care immunoassay/molecular platform with a small benchtop reader and microfluidic test strips — overlapping with TrueDX's POC strategy but with a higher-priced, connected design targeting global health and primary care.

TypeDirect peer
Description

Mesa Labs' Diagnostics segment (including AccuClean and related rapid lateral flow readers) competes in benchtop and field rapid diagnostic readers, broadly comparable to TrueDX's TrueDXP Disposable Reader and TrueDX Reader product family.

TypeDirect peer
Description

Akers Biosciences has historically developed rapid, disposable, single-use point-of-care diagnostic test readers and cartridges — very similar in product architecture and OTC/POC commercial positioning to TrueDX's disposable reader strategy.

TypeEmerging player
Description

GenMark's ePlex system pioneered a sample-to-answer cartridge-plus-reader model for syndromic and infectious disease diagnostics, a useful analog for how a small TrueDX-like platform can be scaled or acquired once menu and clinical evidence mature.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

True Diagnostics

In-Vitro Immunodiagnosticstruediag.com

True Diagnostics is a Carlsbad, California-based developer and manufacturer of rapid in-vitro immunodiagnostic test systems built on its patented TrueDX multi-point calibration platform, serving point-of-care providers, OTC self-testers, OEM partners, and government biodefense programs.

What True Diagnostics does

True Diagnostics, Inc. is a privately held research, development, and manufacturing company founded in 2010 and headquartered in Carlsbad, California, specializing in rapid in-vitro immunodiagnostic test systems. The company builds its products around the proprietary TrueDX platform, anchored by a patented multi-point integrated calibration method that converts conventional qualitative lateral flow assays into quantitative tests with 18-month room-temperature shelf stability. The product portfolio includes the TrueDX Cassette, the TrueDXP Disposable Reader (a hand-held digital reader with OLED display and optional Bluetooth), the higher-spec TrueDX Reader (CMOS sensor, resistive touch screen, QC check, optional Wi-Fi), and supporting modules TrueDXQDF (quantum dot fluorescence for ~100x photo-bleaching stability vs. organic dyes) and TrueDXM (multiplexed picoliter-volume liquid handling). Assay menu spans thyroid, cardiac, cancer, fertility, and biologics monitoring panels.

True Diagnostics firmographics

Firmographics
Name
True Diagnostics
Legal name
True Diagnostics, Inc.
Website
https://truediag.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
True Diagnostics is a Carlsbad, California-based developer and manufacturer of rapid in-vitro immunodiagnostic test systems built on its patented TrueDX multi-point calibration platform, serving point-of-care providers, OTC self-testers, OEM partners, and government biodefense programs.
Ownership category
akta.pro rank

True Diagnostics industry classification

Industry
Product category
In-Vitro Immunodiagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAJ
Companion Diagnostics (CDx) & Precision Medicine IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization

Keywords

  • Rapid immunoassays
  • Point-of-care diagnostics
  • In-vitro immunodiagnostics
  • Lateral flow assays
  • Diagnostic test readers

Where True Diagnostics is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices1 record

Markets served

True Diagnostics business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Test Systems and Reagents: Research, development and manufacturing company specializing in rapid in-vitro immunodiagnostic test systems and reagents. Revenue generated from sale of proprietary diagnostic cassettes, disposable readers, and assay reagents.
  2. Over-the-Counter Products: Disposable readers and test products sold through retail pharmacy chains for consumer self-testing.
  3. Partnership Development Services: Provides design, development, and manufacturing services for assay development to commercial partners. Partners with companies to develop tests with tough specifications including high sensitivity, quantification, multiplexing, and extended shelf life stability.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels1 record

True Diagnostics product offering

Product offering

Core offering

True Diagnostics is a research, development, and manufacturing company that develops and produces proprietary rapid in-vitro immunodiagnostic test systems and reagents. Its core offering centers on the TrueDX platform—patented lateral-flow cassettes with integrated calibration paired with hand-held digital readers—and a menu of quantitative assay panels (thyroid, cardiac, cancer markers, fertility, biologics) sold to clinical providers, OTC retail consumers, and commercial assay-development partners.

Product overview

True Diagnostics is a research, development, and manufacturing company specializing in rapid in-vitro immunodiagnostic test systems. The core product portfolio is built around the proprietary TrueDX technology platform, which includes the TrueDX Cassette (lateral flow test with patented internal calibration), paired with the TrueDXP Disposable Reader (hand-held digital reader with OLED display and optional Bluetooth) and the TrueDX Reader (higher-specification platform with CMOS sensor and touch screen). Supporting modules include TrueDXQDF (quantum dot fluorescence enhancement for improved sensitivity) and TrueDXM (multiplexing capability). The company offers a range of TrueDX Assays spanning thyroid (TSH, Free-T4), cardiac (NT-proBNP, CKMB, Troponin I, Myoglobin), cancer (PSA, AFP, CEA), fertility (HCG), and biologics monitoring (Rituximab, Natalizumab, Trastuzumab) profiles. All assays are stable at room temperature for up to 18 months.

Differentiator

Problem solved

Functional benefit

Brands

  • TruDia: Brand name used in logo and product references
  • TrueDX
  • TrueDXP
  • TrueDXQDF
  • TrueDXM
  • TrueDXP Disposable Reader
  • TrueDX Reader
  • TrueDX Assays

Products and services

  • TrueDX Cassette
  • TrueDXP Disposable Reader
  • TrueDX Reader
  • TrueDX Assays
  • TrueDXQDF Quantum Dot Fluorescence System
  • TrueDXM Multiplexed Assay System

Quantifiable outcome

  • All TrueDX Assays stable at room temperature for up to 18 months
  • +2 more outcomes

Companies that use True Diagnostics

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

True Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

True Diagnostics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 20 October 2025BARDA awarded True Diagnostics a project valued at approximately $11 million to develop a rapid diagnostic test capable of detecting Ebola and Marburg viruses. The project focuses on accelerating biothreat response and supporting future outbreak preparedness. This represents a significant government partnership for advanced diagnostic development.
  • Abreos BiosciencescoreStrategic or Co-development PartnerBrad Messmer, CEO of Abreos Biosciences, is quoted endorsing the TrueDX technology platform, stating it bridges the gap between the ease and speed of traditional qualitative lateral flow assays and the quantitative rigor needed for clinical assays. Abreos appears to be an early adopter and strategic user of the technology.
  • Global PartnersminorOEM/ Whitelabel/ Licensing PartnerCompany states that global partners entrust them with concepts, design, development, manufacturing and support processes to grow their iconic brands. These are unspecified commercial partnerships for assay development and manufacturing services.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

True Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • QuidelOrtho: QuidelOrtho is a major diagnostics company with a broad rapid immunoassay and point-of-care testing portfolio (e.g., Sofia, Triage), directly overlapping with TrueDX's POC and OTC diagnostic positioning and serving similar physician office, urgent care, and retail channels.
  • Abbott (Diagnostics): Abbott operates the largest point-of-care diagnostics franchise globally, including the i-STAT system, Binax Now, and extensive OTC rapid tests — a dominant incumbent against whom TrueDX's POC and OTC reader must compete for hospital and retail shelf space.
  • Becton, Dickinson and Company (BD): BD's Diagnostic Systems segment includes the Veritor point-of-care immunoassay platform and a large biodefense/CDC product portfolio, making it both a competitor in POC diagnostics and a potential federal contracting counterpart to TrueDX on BARDA-style awards.

Direct peers

  • Chembio Diagnostics: Chembio develops rapid point-of-care immunodiagnostic tests, including lateral flow assays for infectious disease and biothreat detection — closely comparable to TrueDX's cassette-plus-reader model and BARDA-aligned focus on emerging pathogen preparedness.
  • OraSure Technologies: OraSure is best known for OTC consumer diagnostics (e.g., OraQuick HIV, HCV) sold through retail pharmacy, and also serves biodefense and public health markets — directly parallel to TrueDX's OTC self-test and biothreat segments.
  • Response Biomedical: Response Biomedical develops rapid quantitative immunoassays (RAMP platform) used in point-of-care clinical and biodefense settings — a near-direct comparability to TrueDX's cassette-plus-reader quantitative approach, including cardiovascular and infectious disease markers.
  • Mesa Laboratories: Mesa Labs' Diagnostics segment (including AccuClean and related rapid lateral flow readers) competes in benchtop and field rapid diagnostic readers, broadly comparable to TrueDX's TrueDXP Disposable Reader and TrueDX Reader product family.
  • Akers Biosciences: Akers Biosciences has historically developed rapid, disposable, single-use point-of-care diagnostic test readers and cartridges — very similar in product architecture and OTC/POC commercial positioning to TrueDX's disposable reader strategy.

Emerging players

  • LumiraDx: LumiraDx built a connected point-of-care immunoassay/molecular platform with a small benchtop reader and microfluidic test strips — overlapping with TrueDX's POC strategy but with a higher-priced, connected design targeting global health and primary care.
  • GenMark Diagnostics (acquired by Roche): GenMark's ePlex system pioneered a sample-to-answer cartridge-plus-reader model for syndromic and infectious disease diagnostics, a useful analog for how a small TrueDX-like platform can be scaled or acquired once menu and clinical evidence mature.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights8 records

Customer concentration

True Diagnostics social profiles

Digital presence

True Diagnostics compliance and trust

Trust signal

Compliance2 records

True Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

True Diagnostics leadership team

Management profile

Number of profiles

Profiles1 record

True Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

True Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about True Diagnostics

What does True Diagnostics do?

True Diagnostics is a research, development, and manufacturing company that develops and produces proprietary rapid in-vitro immunodiagnostic test systems and reagents. Its core offering centers on the TrueDX platform—patented lateral-flow cassettes with integrated calibration paired with hand-held digital readers—and a menu of quantitative assay panels (thyroid, cardiac, cancer markers, fertility, biologics) sold to clinical providers, OTC retail consumers, and commercial assay-development partners.

Is True Diagnostics a public or private company?

True Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was True Diagnostics founded?

True Diagnostics was founded in 2011. It employs 11 to 50 people.

Where is True Diagnostics based?

True Diagnostics is headquartered in Carlsbad, United States, in the North America region.

How does True Diagnostics make money?

Three revenue lines are on record. Diagnostic Test Systems and Reagents are the primary driver. The others are over-the-Counter Products and partnership Development Services.

Who are True Diagnostics's main competitors?

Broad incumbents on record are QuidelOrtho, Abbott (Diagnostics) and Becton, Dickinson and Company (BD). Direct peers are Chembio Diagnostics, OraSure Technologies, Response Biomedical, Mesa Laboratories and Akers Biosciences. Emerging players are LumiraDx and GenMark Diagnostics (acquired by Roche).

Does True Diagnostics have an API?

No public API is recorded for True Diagnostics.

What industry is True Diagnostics in?

True Diagnostics's product category is In-Vitro Immunodiagnostics. Its primary akta.pro industry code is HLAHAAAJ, Companion Diagnostics (CDx) & Precision Medicine IVD, with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTrue Diagnostics Awarded BARDA RRPV Project to Advance Rapid Biothreat TestTrue Diagnostics, Inc. has been awarded an approximately $11 million Project Award through the Rapid Response Partnership Vehicle (RRPV) consortium, funded by BARDA under the U.S. Department of Health and Human Services, to advance development of the VeriClear EbV MARV Rapid Antigen Test. The 36-month program supports design, verification, and FDA clearance of a next-generation point-of-care diagnostic capable of detecting and differentiating Ebola and Marburg viruses from fingerstick blood samples. The initiative aims to accelerate biothreat pathogen testing response capability and strengthen national preparedness for future outbreak events.PR NewswireU.S. Self-Testing Market to Surpass US$ 11.24 billion by 2028, Says Brandessence Market Research (BMRC)Brandessence Market Research published a report on the U.S. self-testing market, valued at US$ 12.6 billion in 2021 and projected to reach US$ 11.24 billion by 2028, reflecting a negative CAGR of -3.0%. Growth drivers include rising chronic disease prevalence, technological advancements, and increased e-commerce distribution, while concerns about unreliable results act as a restraint. The competitive landscape features Abbott Laboratories, Acon Laboratories Inc., Btnx Inc., Bionime Corporation, Roche Holding AG, Quidel Corporation, True Diagnostics Inc., Thermo Fisher Scientific, and Arkaray Inc.NewswireTrue Diagnostics™ and Veravas, Inc. Announce Strategic Alliance in the Commercialization of VeraTest Biotin™True Diagnostics and Veravas announced a strategic alliance to commercialize VeraTest Biotin, a portable test for biotin interference. The test screens for biotin levels above 15 ng/ml, addressing FDA alerts on biotin skewing diagnostic results. The collaboration aims to improve diagnostic accuracy in point-of-care settings.PR NewswireTrue Diagnostics™ and Veravas, Inc. Announce Strategic Alliance in the Commercialization of VeraTest Biotin™True Diagnostics and Veravas announced a strategic alliance to commercialize VeraTest Biotin, a portable diagnostic test that rapidly screens patient samples for significant biotin levels that may interfere with diagnostic test results. The test leverages True's FDA-cleared TrueDX Reader Platform and Veravas' nano magnetic particle technology, providing qualitative results within five minutes for biotin levels above 15 ng/ml. The companies are continuing to collaborate and expand their portfolios with other organizations to bring additional diagnostic solutions to market.PR NewswireTrue Diagnostics, Inc. Receives FDA 510(k) Clearance to Market VeriClear™ Digital Test Device for Early Result PregnancyTrue Diagnostics, Inc. received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for its VeriClear™ Digital Early Result Pregnancy Test. The device detects human chorionic gonadotropin (hCG) levels as early as six days before a missed period and provides digital results. This marks the third FDA-cleared device for the company in 16 months, expanding its portfolio of point-of-care diagnostic solutions.